Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2022-10-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '金陵药业股份有限公司2022 年第三季度报告' which translates to 'Jinling Pharmaceutical Co., Ltd. 2022 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial indicators for the third quarter of 2022. The document explicitly states it is a quarterly report and is unaudited. The length of the document (over 12,000 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-27 Chinese
金陵药业股份有限公司关于控股子公司投资实施装饰装修医技楼及及改扩建感染楼（发热门诊）项目的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding an investment by its controlling subsidiary in renovation and expansion projects for hospital buildings. It details the investment amount, project scope, board approval, and expected impact. There are no financial statements, quarterly or annual results, or audit information. The document is an announcement of a corporate investment project, not a financial report or regulatory filing about financial results or governance changes. It is not a report publication announcement since it contains substantive information about the investment decision and project details. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2022-10-14 Chinese
金陵药业股份有限公司第八届监事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 16th meeting of the 8th Supervisory Board of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting notice, attendance, voting results, and compliance with legal and regulatory requirements. The content is focused on board-level decisions and meeting resolutions rather than financial results, audit opinions, or shareholder voting outcomes. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2022-10-14 Chinese
金陵药业股份有限公司第八届董事会第二十三次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 23rd meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results, and the approval of an investment project by a subsidiary. There is no financial data or detailed management discussion, nor is it a report or presentation. It is clearly a Board/Management Information announcement about board meeting decisions and resolutions. The document length is short and focused on board meeting outcomes, fitting the Board/Management Information (MANG) category.
2022-10-14 Chinese
金陵药业股份有限公司关于收到部分拆迁补偿款的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of partial demolition compensation payments. It details specific amounts received on certain dates and references prior announcements. The document does not contain financial statements or comprehensive financial analysis but is an update on a specific financial event affecting the company. The length is short (1072 characters), and it is an announcement of a financial event rather than a full report. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Capital Update.
2022-09-30 Chinese
金陵药业关于公司及子公司使用闲置资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase low-risk financial products. It includes details about the amounts invested, dates, risk disclosures, and risk control measures. The document is relatively short (2780 characters) and focuses on a specific financing activity related to the company's capital management rather than comprehensive financial results or reports. It does not contain full financial statements or detailed financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP).
2022-08-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.